Valuing the Economic Costs of Allergic Rhinitis, Acute Bronchitis, and Asthma from Exposure to Indoor Dampness and Mold in the US.
Two foundational methods for estimating the total economic burden of disease are cost of illness (COI) and willingness to pay (WTP). WTP measures the full cost to society, but WTP estimates are difficult to compute and rarely available. COI methods are more often used but less likely to reflect full costs. This paper attempts to estimate the full economic cost (2014$) of illnesses resulting from exposure to dampness and mold using COI methods and WTP where the data is available. A limited sensitivity analysis of alternative methods and assumptions demonstrates a wide potential range of estimates. In the final estimates, the total annual cost to society attributable to dampness and mold is estimated to be $3.7 (2.3-4.7) billion for allergic rhinitis, $1.9 (1.1-2.3) billion for acute bronchitis, $15.1 (9.4-20.6) billion for asthma morbidity, and $1.7 (0.4-4.5) billion for asthma mortality. The corresponding costs from all causes, not limited to dampness and mold, using the same approach would be $24.8 billion for allergic rhinitis, $13.5 billion for acute bronchitis, $94.5 billion for asthma morbidity, and $10.8 billion for asthma mortality.
The Cadmus Group, Inc., 2909 Pierpont St, Alexandria, VA 22302, USA.
David H
0000-0001-7590-837X
DH
Mudarri
D000208:Acute Disease / Q000191:economics; D001249:Asthma / Q000191:economics* / Q000209:etiology / Q000382:microbiology; D001991:Bronchitis / Q000191:economics* / Q000209:etiology / Q000382:microbiology; D017281:Cost of Illness; D005658:Fungi / Q000502:physiology*; D006801:Humans; D006813:Humidity / Q000009:adverse effects*; D065631:Rhinitis, Allergic / Q000191:economics* / Q000209:etiology / Q000382:microbiology; D014481:United States